Vizgen, a spatial multi-omics company, announced it has closed a $48 million financing led by ARCH Venture Partners and co-led by M Ventures and Northpond Ventures, with participation from existing investors.
Vizgen said the proceeds will support its innovation roadmap, expand its ability to serve researchers globally, and scale manufacturing operations as demand for spatial biology tools used in basic research and drug discovery grows.
The company said it has recently advanced its commercial and scientific footprint through launches and expanded offerings, including its MERFISH 2.0 chemistry, additions to its InSituPlex and STARVUE proteomics portfolio, and more than 100 new peer-reviewed publications. Vizgen also highlighted partnerships and scientific collaborations across academia and industry.
Vizgen said the new capital follows the resolution of prior litigation and will support efforts to improve customer experience and move the business toward profitability. The company’s platform lineup includes the MERSCOPE system for in situ single-cell spatial genomics, as well as newer product updates referenced by investors, including MERSCOPE Ultra and MERFISH 2.0.
KEY QUOTES:
“Vizgen pioneered single-cell spatial genomics in 2022 with its launch of the MERSCOPE platform, and the company remains an industry leader because of its sustained innovation and scientific rigor. The launch of MERSCOPE Ultra and MERFISH 2.0 are examples of Vizgen continuing to set the standard for technical excellence in the rapidly growing spatial biology field.”
Keith Crandell, Co-founder and Managing Director, ARCH Venture Partners
“We remain highly committed as Vizgen enters this exciting next chapter. The company is now well-positioned to accelerate growth, achieve profitability, and unlock the full potential of its commercial portfolio and R&D pipeline, enabling researchers worldwide to explore cellular functions and interactions with unprecedented clarity and resolution.”
Christian Uhrich, Investment Director, M Ventures
“After a remarkable 15 months of accomplishment, the entire Vizgen team is excited to start 2026 with the capital we need to scale our platform and deliver customer experience excellence to scientists worldwide. With the successful resolution of our prior litigation and now this important financing behind us, we are on a march to profitability. We have a clear path forward and the resources to execute on our vision of making spatial multi-omics an essential tool, accessible to every research lab.”
Rob Carson, CEO, Vizgen
